Bioactive Products
| A unique collection of 69 Antiangiogenic natural compound library for Antiangiogenic screening | ||
| Catalog No: | B94 | Antiangiogenic Compound Library Screening Details |
| Size: | 1mg/well * 69 Compounds 2mg/well * 69 Compounds | |
| Cat. No. | Information |
| CFN98686 | Curcumin Curcumin is a natural phenolic compound with diverse pharmacologic effects including antitumour, anti-bacteria, anti-fungicidal ,anti-edemic, hepatoprotective, anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetylatransferase ((HATs)) and also shows inhibitory effects on NF-κB and MAPKs.Curcumin application causes markedly fast wound closure with well-formed granulation tissue dominated by fibroblast proliferation, collagen deposition, and complete early regenerated epithelial layer. |
| CFN98598 | Theaflavine-3,3'-digallate Theaflavin-3,3'-digallate is a potent AMP-activated protein kinase (AMPK) activator with anti-adiposity activity in adipocytes, suggesting its potential application in functional foods and nutraceuticals for obesity management. Theaflavin-3,3'-digallate is also an inducer of oxidative stress and apoptosis, it has strong antioxidant and antiangiogenic activities, it inhibits the tube formation of endothelial cells via decreased both MMP-2 and MMP-9 activities in vitro. A combination microbicide containing theaflavin-3,3'-digallate and lactic acid can reduce herpes simplex virus (HSV) transmission. Theaflavin-3,3'-digallate may exert its anti-inflammatory and cancer chemopreventive actions by suppressing the activation of NFkappaB through inhibition of IkappaB kinase (IKK) activity. Theaflavin-3,3'-digallate can repress osteoclastogenesis and prevent wear debris-induced osteolysis via suppression of ERK pathway, it is a promising candidate for the treatment of osteoclast-related osteolytic diseases, such as wear debris-induced peri-implant osteolysis (PIO). |
| CFN00085 | Lavendustin A Lavendustin A is a potent tyrosine kinase inhibitor of the epidermal growth factor (EGF) receptor, and an angiogenesis inhibitor. Lavendustin A is also a hyperbolic mixed-type inhibitor with respect to both ATP and the peptide substrate, with a major effect on the binding affinities for both substrates. Lavendustin A at 0.1 nM-1 microM causes a concave-shaped inhibition of the insulin release stimulated by 7 mM glucose, the inhibitory effect can be overcomed by higher concentrations of glucose. Lavendustin A and hormothamnione exhibit cytotoxic effects on tumor cell lines. |
| CFN98913 | Lupeol 1. Lupeol has a potential to act as an anti-inflammatory, anti-microbial, anti-protozoal, anti-proliferative, anti-invasive, anti-angiogenic, antimalarial and cholesterol lowering agent. 2. Lupeol prevents acetaminophen-induced in vivo hepatotoxicity by altering the Bax/Bcl-2 and oxidative stress-mediated mitochondrial signaling cascade. 3. Lupeol and its ester derivative have beneficial effects on hypercholesterolemia-induced oxidative and inflammatory stresses. 4. Lupeol significantly enhances the radiosensitivity of SMMC-7721 cells in vitro and in vivo. 5. Lupeol shows antidiabetic and antioxidant potential in experimental hyperglycaemia. 6. Lupeol has potential anticancer effect against hepatocellular and pancreatic cancer, by inhibiting cell proliferation, inducing apoptosis and blocking Akt/PI3K and Wnt signaling pathway. 7. Lupeol has antiangiogenic effects, it (at 50 and 30 microg/mL) shows a marked inhibitory activity on human umbilical venous endothelial cells (HUVEC) tube formation while it does not affect the growth of tumor cell lines such as SK-MEL-2, A549, and B16-F10 melanoma. |
| CFN00133 | Pramanicin Pramanicin, an antimicrobial agent, has vasorelaxant effect, it induces a slow endothelium-dependent relaxation, which could be reversed with the NO synthase inhibitor, L-NOARG, it has potent, selective, and irreversible inhibitory effect on the endothelial.Pramanicin as a potential apoptosis-inducing small molecule, which acts through a well-defined JNK- and p38-dependent apoptosis signalling pathway in Jurkat T leukemia cells. |
